Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications

Dawn A. Kirschmann, Elisabeth A. Seftor, Katharine M. Hardy, Richard E.B. Seftor, and Mary J.C. Hendrix

Abstract

Tumor cell vasculogenic mimicry (VM) describes the functional plasticity of aggressive cancer cells forming de novo vascular networks, thereby providing a perfusion pathway for rapidly growing tumors, transporting fluid from leaky vessels, and/or connecting with endothelial-lined vasculature. The underlying induction of VM seems to be related to hypoxia, which may also promote the plastic, transendothelial phenotype of tumor cells capable of VM. Since its introduction in 1999 as a novel paradigm for melanoma tumor perfusion, many studies have contributed new insights into the underlying molecular pathways supporting VM in a variety of tumors, including melanoma, glioblastoma, carcinomas, and sarcomas. In particular, critical VM-modulating genes are associated with vascular (VE-cadherin, EphA2, VEGF receptor 1), embryonic and/or stem cell (Nodal, Notch4), and hypoxia-related (hypoxia-inducible factor, Twist1) signaling pathways. Each of these pathways warrants serious scrutiny as potential therapeutic, vascular targets, and diagnostic indicators of plasticity, drug resistance, and the aggressive metastatic phenotype. Clin Cancer Res; 18(10); 1–7. ©2012 AACR.

Background

Vasculogenic mimicry defined

Cancer deaths primarily result from metastases that are resistant to conventional therapies. Indeed, the accepted tenet underlying tumor survival has been that a blood supply is required to sustain growth and to metastasize (1). This important premise ignited the field of neoplastic angiogenesis research, which focused on targeting endothelial cells forming the neovasculature of growing tumors, and served as the major organizing principle for drug discovery and development and clinical trials. However, the disappointing results of the angiogenesis inhibitor trials, together with new findings generated from sophisticated animal models of human tumor progression, have given us novel insights into the molecular mechanisms underlying the perfusion of tumors, particularly those expressing the aggressive metastatic phenotype. One of the new paradigms that has emerged, called "vasculogenic mimicry," also referred to as "vascular mimicry" (VM), describes the de novo formation of perfusable, matrix-rich, vasculogenic-like networks by aggressive tumor cells in 3-dimensional matrices in vitro, which parallels matrix-rich networks in patients’ aggressive tumors (2). The initial morphologic and molecular characterization of VM was made in human melanoma in which the tumor cells were shown to coexpress endothelial and tumor markers and formed channels, networks, and tubular structures that are rich in laminin, collagen IV and VI, and heparin sulfate proteoglycans, containing plasma and red blood cells, indicating a perfusion pathway for rapidly growing tumors, as well as an escape route for metastasis (2–4). Interestingly, these findings agree with very early reports by others suggesting the perfusion of melanoma tumors via nonendothelial-lined channels (5). Since the introduction of VM, a plethora of studies have contributed mechanistic insights into the induction, formation, and targeting of VM across a variety of cancers, including melanoma; sarcomas (Ewing, mesothelial, synovial, osteosarcoma, alveolar rhabdomyosarcoma); carcinoma(s) of the breast, ovary, lung, prostate, bladder, and kidney; and gliomas, glioblastoma, and astrocytoma (reviewed in refs. 6–8). From the extensive literature across this vast field, we now appreciate that the tumor vasculature is highly complex and can be derived from a variety of sources, including angiogenic vessels, cooption of preexisting vessels, intussusceptive microvascular growth, mosaic vessels lined by both tumor cells and endothelium, postnatal vasculogenesis, and VM (9, 10). Furthermore, recent studies have shown the tumor origin of endothelial-like cells in specific cancers (11, 12), thus confounding our strategies for targeting a genetically unstable and heterogeneous vasculature.

Underlying plastic phenotype

Tumor cells capable of VM exhibit a high degree of plasticity, indicative of a multipotent phenotype similar in
many respects to embryonic stem cells (4, 13, 14). Molecular profiling of the tumor cell VM phenotype has revealed highly upregulated genes associated with embryonic progenitors, endothelial cells, vessel formation, matrix remodeling, and hypoxia, and downregulated genes generally associated with the respective, lineage-specific phenotype, such as in the case of melanoma in which several melanocyte-lineage genes are suppressed (15). Confirmation of these genes was achieved by laser capture microdissection and microgenomics profiling of living melanoma cells compared with endothelial cells forming vascular networks, where the expression of specific angiogenesis-related genes in melanoma resembled that of normal endothelial cells (15). In addition, we confirmed that plastic tumor cells express key pluripotent stem cell markers. However, unlike normal embryonic progenitors, these tumor cells lack major regulatory checkpoints, resulting in the aberrant activation of embryonic signaling pathways, such as Nodal and Notch, which underlies their stem cell–like phenotype, unregulated growth, and aggressive behavior (16).

Functional relevance of vascular mimicry

The presence of VM in patients’ tumor tissues has been associated with a poor clinical outcome and suggests a possible advantage imparted by VM with respect to the survival of the aggressive tumor cell phenotype. Indeed, experimental evidence has shown a physiologic perfusion of blood between endothelial-lined mouse vasculature and VM networks in human tumor xenografts using Doppler imaging of microbead circulation (17). Additional studies identified the anticoagulant properties of tumor cells that line VM networks, discussed under the heading of "Vascular Signaling Pathways." Thus, VM can provide a functional perfusion pathway for rapidly growing tumors by transporting fluid from leaky vessels and/or connecting with endothelial-lined vasculature. A remarkable example of VM functional plasticity was achieved by transplanting human metastatic melanoma cells into a circulation-deficient mouse limb, which resulted in the formation of a human melanoma–mouse endothelial chimeric neovasculature (18). Subsequent to the restoration of blood flow to the limb, the tumor cells formed a large tumor mass. Thus, this study highlighted the powerful influence of the microenvironment on the transendothelial differentiation of melanoma cells that reverted to a tumorigenic phenotype as the environmental cues changed.

The multipotent phenotype underlying VM is supported by a complex cooption of signaling pathways that are normally restricted to developmental or cell-specific lineages. In particular, critical VM modulating genes can be categorized into pathways associated with vascular, embryonic and/or stem cell, and hypoxia signaling (Fig. 1). Although a myriad of genes associated with VM have been reported, this review focuses on these 3 pathways that have overarching effects on the VM phenotype, are capable of modulating each other, and have the greatest potential for therapeutic intervention based on rigorous scientific scrutiny.

Vascular Signaling Pathways

One of the first vascular-associated genes shown to be involved in VM is VE-cadherin (CDH15). VE-cadherin is a transmembrane glycoprotein of the cadherin family that promotes homotypic cell–cell interactions and is considered specific for vascular endothelia and critical for vascularigenic events. Interestingly, VE-cadherin is expressed in aggressive, but not nonaggressive melanoma cells, and knockdown of VE-cadherin expression inhibits VM (19). VE-cadherin regulates erythropoietin-producing hepatocellular carcinoma-A2 (EphA2) activity by mediating its ability to become phosphorylated through interactions with its membrane-bound ligand Ephrin-A1 (20). Phosphorylated EphA2 subsequently activates phosphoinositide 3-kinase (PI3K), upregulates matrix metalloproteinase (MMP)14 expression, and activates MMP2. Both MMP14 and MMP2 promote the cleavage of laminin 5γ2-chain into promigratory γ2γ2γ2 and γ2γ2γ2 fragments, which in turn stimulate migration, invasion, and VM in melanoma cells (21). In addition, VE-cadherin expression and activity are enhanced by binding of the transcription factor Twist1 to the VE-cadherin promoter, whereas downregulation of Twist1 expression leads to decreases in VE-cadherin, MMP2, and MMP9 expression and VM formation in human hepatocellular carcinoma cells (22).

VEGF-A is 1 of a family of 5 angiogenic growth factors that plays a crucial role in tumor angiogenesis by recruiting and stimulating the proliferation of endothelial cells in avascular regions of rapidly growing tumors. VM is dependent on the autocrine production of VEGF-A in melanoma (23), whereas, in ovarian cancer cells, VEGF-A treatment promotes VM by upregulating the expression of VE-cadherin, EphA2, and MMP2 and MMP9, showing that VEGF-A can stimulate tumor cell plasticity (24). In mammary and pancreatic islet carcinoma cells, inhibiting EphA2 expression and/or activity leads to a decrease in VEGF expression and VEGF-induced angiogenesis in vivo (25, 26). This suggests that, depending on the tumor cell type, VEGF signaling or EphA2 activation may provide the initiating event in VM formation, though further studies are needed to specifically address this possibility. In addition to EphA2, COX-2 can also upregulate VEGF expression in a variety of tumor cell types via activation of protein kinase C (PKC; ref. 27). COX-2 catalyzes the conversion of arachidonic acid into prostaglandin H2, which is subsequently converted into primarily prostaglandin E2 (PGE2). COX-2 and PGE2 are upregulated in aggressive cancers and are associated with a decrease in cellular apoptosis and an increase in tumor proliferation, invasion, and angiogenesis. These processes are mediated by the family of prostanoid receptors (EP1–4), which activate EGF receptor (EGFR)–mediated signaling, as well as PKC-dependent activation of extracellular signal-regulated kinase (ERK1/2; ref. 28). Invasive breast cancer cells that express high levels of COX-2 form
VM networks, whereas knockdown of COX-2 expression or catalytic activity inhibits VM, which can be rescued with PGE2 (29, 30). Interestingly, EP3, but not EP4, has been shown to regulate VM network formation by aggressive inflammatory breast cancer cells; however, the underlying signaling pathway(s) by which COX-2/PGE2/EP3 promote(s) VM and possibly VEGF expression requires further study.

VEGF receptor tyrosine kinases (VEGFR1 and VEGFR2) bind VEGF-A in an autocrine or paracrine manner and show diverse signaling capacities (VEGF-A has a high binding affinity to VEGFR1, but weak kinase activity), and many VEGFR1-interacting signal transducers have been identified. For example, endothelial cell differentiation and organization into vascular tubes are thought to involve VEGFR1 activation of the PI3K/Akt pathway, whereas cancer cell invasion and migration have been shown to involve VEGFR1 activation of Src and ERK1/2 pathways (31). VEGFR1, but not VEGFR2, mediates VEGF-A–induced VM in melanoma cells, and it has been postulated that VM is mediated through the synergistic transduction of VEGF-A/VEGFR1/PI3K/PKCα and integrin-signaling pathways (25). Moreover, a subpopulation of melanoma cells (ABCB5+ tumor-initiating cells) has been identified that preferentially expresses VEGFR1 and VEGFR1-mediated signaling, critical in VM, laminin production, and rapid tumor growth (32).

Pigment epithelium-derived factor (PEDF) is a multifunctional, secreted glycoprotein that is part of the noninhibitory family of serine protease inhibitors. PEDF has direct (via suppressing growth by promoting tumor differentiation and apoptosis) and indirect (via suppressing angiogenesis by inducing apoptosis via FasL expression and inhibiting VEGF signaling through VEGFR1) antitumor effects (reviewed in ref. 33). PEDF is expressed on melanocytes and nonaggressive melanoma cells and is downregulated in aggressive melanoma (34). Knockdown of PEDF expression in nonaggressive melanoma cells induces VM, suggesting a linkage to molecular plasticity. Although the functional roles of PEDF are well characterized, the

Figure 1. Model of signaling pathways implicated in tumor cell VM. Only signaling molecules that have been specifically modulated using antisense oligonucleotides, small inhibitory RNAs, blocking antibodies, small-molecule inhibitors, or transient transfections are depicted, showing their ability to directly affect VM, and are categorized as vascular (red), embryonic and/or stem cell (green), and hypoxia signaling pathways (blue). Molecules shaded with 2 different colors show overlap between major VM signaling pathways. Proteins in brown play a quintessential role in VM formation and matrix remodeling (21). Question marks indicate the potential involvement of a protein and/or downstream effector proteins in modulating VM in aggressive cancer cells, in which the underlying signaling pathway(s) are not as yet clearly defined. A portion of this model was used in our previous publication, Dome et al. (9). FAK, focal adhesion kinase.
underlying signaling pathways, with respect to inhibiting VM, remain to be elucidated.

Tissue factor (TF), TF pathway inhibitor 1 (TFPI-1), and TFPI-2 are quintessential genes that initiate and regulate coagulation pathways, and all 3 of these genes are upregulated in aggressive melanoma cells (17). The procoagulant function of TF was shown to be regulated by TFPI-1 and is thought to contribute to the fluid-conducting potential in VM networks. However, whereas TFPI-2 did not inhibit TF coagulation, it was found to be required for VM tubular network formation, presumably through matrix remodeling, because inhibition of TFPI-2 expression suppressed MMP 2 activity. These studies suggest a novel mechanism for matrix-associated TFPI-2 in VM.

Embryonic and/or Stem Cell Pathways

Nodal signaling pathways are important regulators of human embryonic pluripotency and vertebrate embryonic development (35, 36). Nodal is a growth factor of the TGFβ superfamily that binds Cripto-1 and activates type I and type II activin-like kinase receptors (ALK4/5/7 and ActRIBB, respectively), which subsequently propagates canonical signaling via Smad2/3. This embryonic pathway has been shown to participate in tumor progression and aggressive tumor cell behavior, including VM (16, 37, 38). Treatment of aggressive melanoma cells with a function-blocking anti-Nodal antibody reduces their ability to engage in VM, implicating Nodal as an important regulator of tumor cell plasticity and the transendothelial phenotype (38). During embryonic development, Nodal expression is influenced by Notch (39). The Notch family consists of 4 transmembrane receptors (Notch1–4), whose signaling pathways are critical regulators of vertebrate embryogenesis. Notch signaling is initiated by binding of a Notch ligand, which is a series of cleavages that generate the release of the Notch intracellular domain (NICD) that translocates to the nucleus and regulates the expression of a number of context-dependent targets, including Nodal (38–40). Inhibition of Notch4 function downregulates Nodal and VE-cadherin expression and impairs VM network formation by aggressive melanoma cells (16). Because Notch4 functions primarily in vascular development (40) and is enriched in the subpopulation of melanoma cells that form VM (16), Notch4–Nodal signaling may represent a master regulator of VM.

Hypoxia and/or Hypoxia-Reoxygenation–Signaling Pathways

Hypoxia, either persistent or transient, is a hallmark of most tumors and has been shown to regulate pathways in the maintenance of the stem cell–like phenotype, cellular differentiation, invasion, metastasis, apoptotic resistance, genomic instability, angiogenesis, and VM. Molecularly, protein stabilization and nuclear localization of hypoxia-inducible factor-1α (HIF-1α)/HIF-2α transcription factors and binding to hypoxia response elements (HRE) in promoter and enhancers of effector genes occurs in response to low oxygen, oncogenes, or inactivated tumor suppressor genes (reviewed in ref. 41). Hypoxia has been shown to induce VM in hepatocellular carcinoma (42), Ewing sarcoma (43), and melanoma (44). Moreover, hypoxia can induce a dedifferentiated phenotype in breast carcinoma (45). Pertinent to VM, hypoxia has been shown to either directly modulate VEGF-A, VEGFR, EphA2, Twist, Nodal, and COX-2 gene expression (via HIF-1/HRE binding) or indirectly modulate VE-cadherin and TF expression (via activation of an intermediary protein). Hypoxia can also modulate the expression of Notch-responsive genes; specifically, hypoxia stabilizes the NICD protein, which interacts with HIF-1α and activates genes with Notch-responsive promoters, including Nodal (46, 47). This noncanonical cross-talk between HIF-1α and Notch-signaling pathways is thought to promote an undifferentiated cell state, further illuminating the possible etiology of tumor cell plasticity underlying VM. Based on the numerous studies showing hypoxia-induced VM and/or VM-associated genes, it is conceivable that therapeutic use of antiangiogenic agents may promote tumor plasticity and metastatic progression.

Clinical–Translational Advances

The plastic phenotype of aggressive tumor cells has presented a significant challenge in the detection and targeting of the transdifferentiated endothelial phenotype, manifested as VM. Although the premise of suppressing a tumor’s blood supply by targeting endothelial cells forming angiogenic vessels seems strategically viable, experimental evidence indicates that hypoxia induced by depriving tumors of oxygen promotes invasion and metastasis (48), as well as VM. Moreover, the lackluster results of cumulative clinical trials with angiogenesis inhibitors further show the need for new therapeutic strategies based on recent scientific breakthroughs. Other avenues of investigation have tested the effects of the classical angiogenesis inhibitors endostatin and TNP-470 on melanoma VM in a side-by-side comparison with normal endothelial cells and shown that these inhibitors do not suppress VM, because the tumor cells lack the appropriate level of receptors for the inhibitors to act effectively (49). Furthermore, recent findings revealed that treatment of human breast cancer xenografts with bevacizumab and sunitinib resulted in intratumoral hypoxia and increased breast cancer stem cells (50). These basic observations should serve as a critical caveat in the development of new vascular-disrupting agents and/or combinatorial approaches. Certainly, the molecular pathways that have been experimentally identified as critically involved in VM serve as a strategic roadmap for drug development (shown in Fig. 1), together with investigative observations generated from the testing of select U.S. Food and Drug Administration (FDA)–approved angiogenesis inhibitors (Table 1).

There is experimental evidence that specifically targeting pathways implicated in VM may have success in inhibiting tumor growth. Certainly, a handful of preclinical studies suggest that specific compounds affecting components of the previously described vascular, embryonic, or hypoxia
pathways in tumor cells can inhibit VM formation in cancer models. For example, plant-derived compounds such as genistein (an isoflavone found in soy) or curcumin (derived from the spice turmeric), have been shown to reduce VM channel formation in melanoma cell lines in vitro and in vivo, concurrent with a downregulation of VE-cadherin, EphA2, or MMPs, depending on the agent (51, 52). Likewise, FDA-approved angiogenesis inhibitors that have specifically suppressed tumor cell VM include thalidomide (a teratogenic sedative and a reactive oxygen species producer specifically suppressed tumor cell VM include thalidomide (a teratogenic sedative and a reactive oxygen species producer (53, 54). Similarly, treatment of glioblastoma cells with bevacizumab had no effect on the ability of glioblastoma stemlike cells to transdifferentiate into endothelial-like precursors. (57). Our work has shown that treatment of Notch4-expressing aggressive melanoma cell lines with anti-Notch4 antibodies reduces VM formation in vitro, likely via regulation of Nodal expression (16). It is exciting to speculate that in vivo combinatorial therapy of anti-Notch4 or anti-Nodal plus VEGF inhibitors might simultaneously target tumor angiogenesis and VM in melanoma, and potentially other cancers. Certainly, as many have wisely advised, multiple signaling pathways should be targeted in a combinatorial manner to overcome tumor cell plasticity, drug resistance, neoplastic angiogenesis, and metastasis (58, 59).

Simultaneous targeting of the Notch and VEGF pathways may provide a more viable combinatorial approach to target cancer stem cells with anti-VEGF therapy. In glioblastoma, VM likely occurs independently of VEGF expression because VM network formation by mouse glioblastoma cell lines was not inhibited in vitro or in vivo by an anti-VEGF antibody (55). Similarly, treatment of glioblastoma cells with bevacizumab had no effect on the ability of the stemlike subpopulation to transdifferentiate into endothelial-like progenitor cells, but the gamma-secretase inhibitor DAPT could block this phenomenon (12). Combined gamma-secretase and bevacizumab treatment of xenografted glioblastoma and fibrosarcoma cell lines resulted in a significant inhibition of tumor growth compared with either treatment alone, predominantly through blockade of DLL4-Notch signaling (56). Because global gamma-secretase inhibitors can be toxic to intestinal cells, the use of antibodies to specific components of the Notch pathway may prove more desirable. Certainly, combined anti-DLL4 and anti-VEGF treatments in xenografted MV-522 cells had a greater impact on tumor angiogenesis and tumor growth than either alone (57).

## Table 1. FDA-approved angiogenesis inhibitors

<table>
<thead>
<tr>
<th>Therapeutic agents</th>
<th>Molecular targets</th>
<th>Effect on VM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAb therapy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bevacizumab (Avastin; Genentech)</td>
<td>VEGF</td>
<td>No effect (12)a</td>
</tr>
<tr>
<td>Cetuximab (Erbitux; Bristol-Myers Squibb)</td>
<td>EGFR</td>
<td>ND</td>
</tr>
<tr>
<td>Panitumumab (Vectibix; Amgen)</td>
<td>EGFR</td>
<td>ND</td>
</tr>
<tr>
<td>Small-molecule TKIs</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sunitinib (Sutent; Pfizer Oncology)</td>
<td>VEGFRs, PDGFRβ, RET</td>
<td>ND</td>
</tr>
<tr>
<td>Sorafenib (Nexavar; Bayer and Onyx Pharmaceuticals)</td>
<td>VEGFRs, PDGFRβ, Raf-1</td>
<td>ND</td>
</tr>
<tr>
<td>Erlotinib (Tarceva; Genentech)</td>
<td>EGFR</td>
<td>ND</td>
</tr>
<tr>
<td>Imatinib (Gleevec/Glivec; Novartis)</td>
<td>TKI, Bcr-Abl</td>
<td>ND</td>
</tr>
<tr>
<td>Gefitinib (Iressa; AstraZeneca)</td>
<td>EGFR</td>
<td>ND</td>
</tr>
<tr>
<td>Pazopanib (Votrient, GW786034; GlaxoSmithKline)</td>
<td>VEGFRs, PDGFRβ, c-Kit</td>
<td>ND</td>
</tr>
<tr>
<td>Lapatinib (Tykerb; GlaxoSmithKline)</td>
<td>EGFR, HER2</td>
<td>ND</td>
</tr>
<tr>
<td>Other angiogenic agents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thalidomide (Thalomid; Celgene)</td>
<td>TNF-α, ROS producer</td>
<td>Inhibits VM (53)</td>
</tr>
<tr>
<td>TNP-470 (AGM-1470; Takeda Pharmaceutical)</td>
<td>TKI</td>
<td>No effect (49)</td>
</tr>
<tr>
<td>Endostatin (Endostar; Simcere Pharmaceutical Group)</td>
<td>Integrin signaling</td>
<td>No effect (49)</td>
</tr>
<tr>
<td>Rapamycin (Sirolimus; Pfizer)</td>
<td>mTOR, VEGF</td>
<td>Inhibits VM (54)</td>
</tr>
</tbody>
</table>

Abbreviations: MAb, monoclonal antibody; ND, not determined; TKI, tyrosine kinase inhibitor.

aNo effect on the ability of glioblastoma stemlike cells to transdifferentiate into endothelial-like precursors.

## Conclusions

Tumor cell VM illustrates the functional plasticity of the aggressive cancer phenotype and serves as a selective combinatorial targeting of the Notch and VEGF pathways to exploit the convergence of embryonic and tumorologic signaling. Suppression of these master plasticity pathways results in the inhibition of VM, tumorigenicity, and the reversion of the stem cell–like phenotype to that of a differentiated cell type (16, 37). Going forward, it is noteworthy to mention that VM can be used as a reliable predictor of tumor cell aggressiveness and as a preclinical screen for vascular-disrupting agents (7, 49, 60). Adding this assay to the armamentarium of current predictive tests for clinical application could provide valuable insights into the effective targeting of tumor cell plasticity.

Conclusions

Tumor cell VM illustrates the functional plasticity of the aggressive cancer phenotype and serves as a selective combinatorial targeting of the Notch and VEGF pathways to exploit the convergence of embryonic and tumorologic signaling. Suppression of these master plasticity pathways results in the inhibition of VM, tumorigenicity, and the reversion of the stem cell–like phenotype to that of a differentiated cell type (16, 37). Going forward, it is noteworthy to mention that VM can be used as a reliable predictor of tumor cell aggressiveness and as a preclinical screen for vascular-disrupting agents (7, 49, 60). Adding this assay to the armamentarium of current predictive tests for clinical application could provide valuable insights into the effective targeting of tumor cell plasticity.

Conclusions

Tumor cell VM illustrates the functional plasticity of the aggressive cancer phenotype and serves as a selective combinatorial targeting of the Notch and VEGF pathways to exploit the convergence of embryonic and tumorologic signaling. Suppression of these master plasticity pathways results in the inhibition of VM, tumorigenicity, and the reversion of the stem cell–like phenotype to that of a differentiated cell type (16, 37). Going forward, it is noteworthy to mention that VM can be used as a reliable predictor of tumor cell aggressiveness and as a preclinical screen for vascular-disrupting agents (7, 49, 60). Adding this assay to the armamentarium of current predictive tests for clinical application could provide valuable insights into the effective targeting of tumor cell plasticity.

Conclusions

Tumor cell VM illustrates the functional plasticity of the aggressive cancer phenotype and serves as a selective combinatorial targeting of the Notch and VEGF pathways to exploit the convergence of embryonic and tumorologic signaling. Suppression of these master plasticity pathways results in the inhibition of VM, tumorigenicity, and the reversion of the stem cell–like phenotype to that of a differentiated cell type (16, 37). Going forward, it is noteworthy to mention that VM can be used as a reliable predictor of tumor cell aggressiveness and as a preclinical screen for vascular-disrupting agents (7, 49, 60). Adding this assay to the armamentarium of current predictive tests for clinical application could provide valuable insights into the effective targeting of tumor cell plasticity.

Conclusions

Tumor cell VM illustrates the functional plasticity of the aggressive cancer phenotype and serves as a selective combinatorial targeting of the Notch and VEGF pathways to exploit the convergence of embryonic and tumorologic signaling. Suppression of these master plasticity pathways results in the inhibition of VM, tumorigenicity, and the reversion of the stem cell–like phenotype to that of a differentiated cell type (16, 37). Going forward, it is noteworthy to mention that VM can be used as a reliable predictor of tumor cell aggressiveness and as a preclinical screen for vascular-disrupting agents (7, 49, 60). Adding this assay to the armamentarium of current predictive tests for clinical application could provide valuable insights into the effective targeting of tumor cell plasticity.

Conclusions

Tumor cell VM illustrates the functional plasticity of the aggressive cancer phenotype and serves as a selective combinatorial targeting of the Notch and VEGF pathways to exploit the convergence of embryonic and tumorologic signaling. Suppression of these master plasticity pathways results in the inhibition of VM, tumorigenicity, and the reversion of the stem cell–like phenotype to that of a differentiated cell type (16, 37). Going forward, it is noteworthy to mention that VM can be used as a reliable predictor of tumor cell aggressiveness and as a preclinical screen for vascular-disrupting agents (7, 49, 60). Adding this assay to the armamentarium of current predictive tests for clinical application could provide valuable insights into the effective targeting of tumor cell plasticity.
advantage for rapidly growing tumors in need of perfusion. VM can provide one of several sources for a tumor’s blood supply that can directly or indirectly interact with other vasculature. The underlying induction of VM seems to be related to hypoxia, which may also promote the plastic, transendothelial phenotype of tumor cells capable of VM. Since its introduction in 1999 as a novel paradigm for tumor perfusion, many studies have contributed new insights into the underlying molecular pathways supporting VM. Each of these pathways warrants serious scrutiny as potential therapeutic targets and diagnostic indicator(s) of plasticity, drug resistance, and the aggressive metastatic phenotype.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors' Contributions
Conception and design: E.A. Seftor, R.E.B. Seftor, M.J.C. Hendrix
Development of methodology: E.A. Seftor, R.E.B. Seftor, M.J.C. Hendrix
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): E.A. Seftor, R.E.B. Seftor
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): E.A. Seftor, R.E.B. Seftor, M.J.C. Hendrix
Writing, review, and/or revision of the manuscript: D.A. Kirschmann, E.A. Seftor, K.M. Hardy
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): R.E.B. Seftor, M.J.C. Hendrix
Study supervision: R.E.B. Seftor, M.J.C. Hendrix
Other (designed and drew figure): D.A. Kirschmann

Acknowledgments
Given the space limitations of the review, the authors sincerely apologize for their inability to cite everyone who has contributed to this field of inquiry.

Grant Support
Research supported by National Cancer Institute R37CA59702, RO1CA121205, and U54CA143869 (M.J.C. Hendrix)

Received December 15, 2011; revised February 16, 2012; accepted March 9, 2012; published OnlineFirst April 2, 2012.

References


28. Smalley KSM, Haass NK, Bratford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 2006;5:1136–44.


Molecular Pathways: Vasculogenic Mimicry in Tumor Cells: Diagnostic and Therapeutic Implications

Dawn A. Kirschmann, Elisabeth A. Settor, Katharine M. Hardy, et al.

Clin Cancer Res  Published OnlineFirst April 2, 2012.

Updated version  Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-11-3237

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.